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Abstract
Objective—Resistin is associated with inflammation and insulin resistance, and exerts direct effects
on myocardial cells including hypertrophy and altered contraction. We investigated the association
of serum resistin concentrations with risk for incident heart failure (HF) in humans.
Methods and Results—We studied 2902 older persons without prevalent HF (age, 73.6±2.9
years; 48.1% men; 58.8% white) enrolled in the Health ABC Study. Correlation between baseline
serum resistin concentrations (20.3±10.0 ng/mL) and clinical variables, biochemistry panel, markers
of inflammation and insulin resistance, adipocytokines, and measures of adiposity was weak (all
rho<0.25). During a median follow-up of 9.4 years, 341 participants (11.8%) developed HF. Resistin
was strongly associated with risk for incident HF in Cox proportional hazards models controlling for
clinical variables, biomarkers, and measures of adiposity (HR, 1.15 per 10.0 ng/mL in adjusted
model; 95%CI, 1.05–1.27; P=0.003). Results were comparable across sex, race, diabetes mellitus,
and prevalent and incident coronary heart disease subgroups. In participants with available left
ventricular ejection fraction at HF diagnosis (265 of 341; 77.7%), association of resistin with HF risk
was comparable for cases with reduced vs. preserved ejection fraction.
Conclusions—Serum resistin concentrations are independently associated with risk for incident
HF in older persons.
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Resistin, a 12.5-kDa polypeptide, was initially discovered in the adipose tissue but now is
known to be produced by other cell types e.g. macrophages.1–3 Resistin concentrations have
been correlated with the risk for coronary heart disease (CHD),4, 5 renal dysfunction,6 and
outcomes among stroke patients.7 Higher concentrations are found in subjects with prevalent
heart failure (HF).8 Although the exact function of resistin is not known, it has been associated
with insulin resistance and inflammation.1, 4 Several markers of inflammation e.g. C- reactive
protein (CRP), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) have been
associated with incident HF.9, 10 Similarly, various measures of insulin resistance are
associated with increased HF risk,11, 12 Thus, resistin may be related to HF risk through
multiple pathways. Interestingly, several direct myocardial effects of resistin have also been
demonstrated.13 In neonatal rats, adenovirus-mediated overexpression of resistin results in
increased sarcomere organization, cell size, and protein synthesis in cardiomyocytes, and
expression of atrial natriuretic factor and beta-myosin heavy chain. Overexpression of resistin
in adult rat cardiomyocytes altered mechanics by depressing cell contractility as well as
contraction and relaxation velocities. Thus it is possible that resistin may confer increased risk
for HF through direct and indirect mechanisms. In this study, we sought to assess the association
between serum resistin concentrations at baseline and development of new onset HF among
older persons in the Health ABC Study.
METHODS
Study Population
The Health ABC Study enrolled 3075 well functioning, community-dwelling individuals aged
70 to 79 years between April 1997 and June 1998. Participants were identified from a random
sample of white Medicare beneficiaries and all age-eligible black community residents in
designated zip codes areas surrounding Pittsburgh and Memphis. Exclusion criteria included
difficulties with activities of daily living, obvious cognitive impairment, inability to
communicate, anticipated move within 3 years, or participation in a trial involving life-style
intervention. The institutional review boards at both study sites approved the protocol.
Participants with HF or missing data on HF at baseline (n=140) were excluded from this
investigation. Of the 2935 participants without prevalent HF, 2905 (99.0%) had available
serum resistin concentrations. Three participants were excluded because of extreme outlying
resistin values; the remaining 2902 participants were included in this study.
Serum Biomarker Measurements
In the Health ABC Study, blood samples were obtained after overnight fasting, frozen at −70°
C, and shipped to the core laboratory at the University of Vermont. Serum resistin concentration
was measured using a sandwich enzyme-linked immunosorbent assay (ELISA) (Linco
Research Inc, St. Charles, MO). Intra- and inter-assay coefficients of variation for this assay
are 4.5% and 7.4%, respectively.14 Cytokines were measured in duplicate by ELISA. The
detectable limit for IL-6 was 0.10 pg/mL and for TNF-a 0.18 pg/mL. Serum concentrations of
CRP were measured in duplicate by ELISA on the basis of purified protein and polyclonal anti-
CRP antibodies. The CRP assay was standardized according to WHO First International
Reference Standard with a sensitivity of 0.08 mg/L. Blind duplicate analyses (n=150) for IL-6,
CRP, and TNF-α showed inter-assay coefficients of variation of 10.3%, 8.0%, and 15.8%,
respectively. Serum leptin and adiponectin concentrations were measured in duplicate by
radioimmunoassay (Linco Research Inc, St Charles, MO).
Measures of Adiposity
Total fat mass was determined with whole-body dual X-ray absorptiometry (DEXA) performed
using the pencil beam technology (QDR 00, Hologic, Waltham, MA). Abdominal visceral and
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subcutaneous adipose tissue areas at the lumbar (L4–L5) level were measured with computed
tomography (CT) using a Somatom Plus 4 (Siemens, Erlangen, Germany) or a Picker PQ 2000S
(Marconi Medical Systems, Cleveland, OH) scanner in Memphis, TN, and a 9800 Advantage
scanner (General Electric, Milwaukee, WI) in Pittsburgh, PA. Scans were conducted at 120
kVp, 200 to 250 mA sec, with 10mm slice thickness. Areas were calculated by multiplying the
number of pixels of a given tissue type by the pixel area using imaging software (RSI Systems,
Boulder, CO). Visceral fat was manually distinguished from subcutaneous fat by tracing along
the fascial plane defining the internal abdominal wall.
Study Definitions
Race was self-defined by the participant. Diabetes mellitus was considered present if the
participant reported a history of diabetes mellitus or use of anti-hyperglycemic medication.
Smoking was defined as current, past (≥100 lifetime cigarettes), or never. Left ventricular
hypertrophy was diagnosed based on electrocardiogram using the following voltage criteria;
R amplitude > 26 mm in either V5 or V6, or R amplitude > 20 mm in any of leads I, II, III,
aVF, or R amplitude > 12 mm in lead aVL or R amplitude in V5 or V6 plus S amplitude in
V1 > 35 mm. Coronary heart disease was defined as; a) history of surgical or percutaneous
revascularization; or b) electrocardiographic evidence of myocardial infarction; or c) self-
reported history of myocardial infarction or angina accompanied by use of antianginal
medications. Hypertension was defined as self-reported history of physician diagnosis
accompanied by use of antihypertensive medications. Incident CHD was defined as
hospitalization for myocardial infarction or angina pectoris, or elective revascularization.
Study Outcome
All participants were asked to report any hospitalizations and every 6 months were asked direct
questions about interim cardiovascular events. Medical records for overnight hospitalizations
were reviewed at each site. All first admissions with an overnight stay that was confirmed as
related to HF were classified as incident HF. Local adjudicators classified HF, based on
symptoms, signs, chest radiograph results, and echocardiographic findings, using criteria
similar to those used in the Cardiovascular Health Study.15 The criteria required at least HF
diagnosis from a physician and treatment for HF.16 All deaths were reviewed by the Health
ABC Study diagnosis and disease ascertainment committee and underlying causes of death
were determined by central adjudication. Information on ejection fraction post-HF
development was abstracted from the hospital medical records during the index hospitalization
and was derived from echocardiography or left ventriculography reports.
Statistical Analysis
The correlation between resistin concentrations with baseline participant characteristics and
other biomarkers was evaluated by non-parametric tests (Spearman’s rank correlation for
continuous and rank sum for binary variables). The univariable relation of resistin to HF risk
was evaluated using Cox proportional hazards models with resistin entered as continuous
variable. For comparison, we also evaluated the univariable relation of inflammatory markers,
insulin resistance markers, adipose tissue hormones, and DEXA- and CT-derived measures of
adiposity with incident HF risk.
In multivariable Cox models, we controlled for four sets of hierarchical, a-priori defined
domains. First, we controlled for independent clinical predictors of incident HF as identified
in the Health ABC HF model.12 Second, we additionally controlled for all baseline clinical
variables with significant (p<0.05) correlation with resistin concentrations. Because resistin is
associated with inflammation and glucose metabolism and possibly provides information that
is collinear with other markers, the third set of variables included also baseline markers of
inflammation (CRP, IL-6, and TNF-α) and insulin resistance (hemoglobin HbA1c and fasting
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insulin concentrations), and adipocytokines (leptin, adiponectin). Finally, because measures
of adiposity might provide prognostic information that overlaps with that provided by resistin,
the fourth set of variables included all previous variables and also CT- (abdominal total,
visceral, and subcutaneous fat area) and DEXA- (total and trunk fat mass, percent body fat)
derived measures of adiposity. In a secondary analysis, we evaluated the association between
resistin and risk for HF with reduced (≤40%) vs. preserved (>40%) left ventricular ejection
fraction. For these analyses, only incident HF cases with documented left ventricular ejection
fraction were considered as events in separate (reduced vs. preserved) Cox models.
All continuous predictors were evaluated for non-linear associations with incident HF risk and
appropriately transformed with fractional polynomials. The proportional hazards assumption
was evaluated by examining the Schoenfeld residuals. For multivariable models, missing
values of covariates were imputed using multiple imputation by chained equations as
introduced by van Buuren et al.17, 18 Parameter estimates and confidence intervals were
obtained by combining 10 imputed datasets using the method described by Barnard and Rubin
to account for possible error in missing value analysis.19 A two-sided P<0.05 was accepted as
statistically significant for all analyses. Analyses were performed with STATA 10 (StataCorp,
College Station, TX).
RESULTS
Baseline Characteristics and Serum Resistin Concentrations
The mean age of participants was 73.6±2.9 years with 48.1% men and 58.8% white. Mean
resistin concentration was 20.3±10.0 ng/mL (median, 18.0; interquartile range [IQR], 14.0 –
24.1; range, 3.0–101.1). Table 1 presents baseline population characteristics and their
correlation with resistin concentrations. Multiple statistically significant but weak correlations
were detected (all rho<0.25).
The serum concentrations of inflammatory markers (CRP, IL-6, TNF-a), insulin resistance
(fasting insulin, hemoglobin A1c) markers, and adipocytokines (leptin, adiponectin) all had
weak correlations with resistin concentrations (Supplementary Table A). Same was true for
DEXA-derived (total fat mass, total fat-free mass, percent body fat, trunk fat mass, trunk fat-
free mass) and CT-derived (total, visceral, and subcutaneous abdominal fat area) measures of
adiposity (Supplementary Table B).
Resistin and Incident Heart Failure
During a median follow-up of 9.4 years (IQR, 7.0–9.4). 341 participants (11.8%) developed
incident HF (14.9 per 1000 person-years). Mean resistin concentration was 24.0±12.7 ng/mL
(median, 21.3; IQR, 15.9–27.7) among participants who developed HF as compared to 19.8
±9.4 ng/mL (median, 17.7; IQR, 13.7–23.1) among those who did not (P<0.001). In univariable
analysis, resistin concentrations had a strong, linear relation with risk for incident HF; HR was
1.37 (95% CI, 1.27–1.47; P<0.001) per standard deviation (10.0 ng/mL) of baseline resistin
concentration. Figure 1 presents the observed HF incidence in the cohort in relation to baseline
resistin concentrations. In a head-to-head, univariable comparison with inflammatory
cytokines, insulin resistance markers, adipose tissue hormones, and adiposity parameters
derived by imaging, resistin was a strong predictor of incident HF compared to all other
markers, second only to interleukin-6 (Table 2).
Resistin concentrations were significantly associated with incident HF after adjustment for
baseline clinical characteristics and predictors of incident HF (Table 3, models 1 & 2). This
relation persisted after controlling for inflammatory cytokines, markers of insulin resistance,
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and adipose tissue hormones (model 3), and after controlling for adiposity parameters derived
by DEXA and CT (model 4).
The association between resistin concentrations and incident HF was similar in sex, prevalent
CHD, and prevalent diabetes mellitus based subgroups (P=0.76, P=0.95, and P=0.97 for the
interaction terms, respectively). Association with incident HF risk was stronger in white as
compared with black participants; this interaction however did not reach statistical significance
(P=0.20 for the interaction term).
Incident Coronary Heart Disease, Resistin, and Heart Failure
In participants without CHD at baseline (n=2383), the unadjusted association of resistin
concentrations with incident HF risk was similar in those who developed CHD during follow-
up (n=316; HR, 1.36; 95% CI, 1.20–1.55; P<0.001) and in those who remained free of CHD
during follow up (n=2067; HR, 1.38; 95% CI, 1.20–1.57; P<0.001); P=0.95 for the interaction
term.
Heart Failure with Reduced vs. Preserved Ejection Fraction
Data on left ventricular ejection fraction at time of HF diagnosis were available in 265 of 341
participants (77.7%). Mean ejection fraction was 42±16% (median: 42, IQR, 30–55); 129/265
participants (48.7%) had ejection fraction ≤40% while 136/265 (51.3%) had ejection fraction
>40%. Baseline resistin concentrations were strongly predictive of incident HF in both
participants with reduced (HR per 10ng/ml resistin concentration 1.35, 95% CI, 1.20–1.53,
P<0.001) and preserved ejection fraction (HR 1.42, 95% CI, 1.27–1.58, P<0.001) in unadjusted
analyses, P=0.58 for the comparison of HR.
Incremental value of Resistin for Incident Heart Failure Prediction
Clinical predictors of incident HF, as identified in the Health ABC HF model,12 had C index
0.718 (95% CI, 0.690–0.747) for HF prediction throughout the follow-up period. Addition of
resistin to this model increased C index to 0.726 (95% CI, 0.697–0.754), P=0.035 for the
increase.
DISCUSSION
In this population-based study, we report an independent association between resistin
concentrations and risk for incident HF among older persons. This association persisted after
controlling for baseline characteristics, predictors for incident HF, markers of inflammation
and insulin resistance, adipocytokines, and multiple measures of adiposity. Our data adds to
the growing literature on the role of serum resistin in modulating cardiovascular risk.
Beyond the statistical association, the true value of “novel” risk markers is their independent
association with outcome. Many markers may provide collinear information affecting common
pathophysiologic pathways. In our study, the correlation of resistin with baseline clinical
variables and biomarkers, although statistically significant in many instances due to the large
sample size, was overall weak. Most importantly, the association between resistin and incident
HF risk persisted after extensive adjustment for possible confounders representing various
disparate pathways. We also observed that resistin was a stronger predictor of incident HF
when directly compared with other biomarkers, with the exception of interleukin-6. Our
findings extend the results of the study by the Framingham investigators,20 which demonstrated
that serum resistin concentrations were associated with risk for HF after controlling for clinical
characteristics, inflammatory markers, and B-type natriuretic peptide levels in a younger
population. Taken together, these findings signal to the strength of association between serum
resistin and incident HF. Although resistin concentrations have been associated with diabetes
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mellitus21 and CHD,5 the degree of association with incident HF in our study was comparable
among prevalent and incident CHD and diabetes mellitus subgroups, a finding that was also
present in the Framingham report.20 Finally, this association was consistent across sex and
race.
Initially it was felt that resistin was derived primarily from adipocytes. Beyond the originally
described “passive” role of storing excess energy, the adipose tissue is an “active” endocrine
organ.20–22 Adipocytokines affect the structure and function of various organ systems. Resistin
expression and serum concentrations are related to obesity, insulin resistance, and
inflammation in humans.23–25 These mechanisms are directly involved in the pathogenesis of
CHD10, 26, 27 and the development and progression of both ischemic and non-ischemic
cardiomyopathy.28, 29 Beyond the indirect effects, overexpression of resistin in
cardiomyocytes has been associated with altered response to ischemia-reperfusion injury,30
depressed contractility,13 and hypertrophy.13 All these observations make our association
between resistin and HF theoretically plausible. Interestingly, considering the weak
correlations that we observed between multiple measures of adiposity and serum resistin
concentrations, it raises the question whether resistin is primarily derived from the adipose
tissue or elsewhere; and indeed multiple other cell types have now been associated with
secretion of resistin e.g. macrophages.2, 3
Multiple reasons for this strong association between serum resistin and risk for incident HF
can be hypothesized. A marker associated with multiple pathways of disease causation may
be stronger in its association with outcomes than those associated with individual pathways.
As discussed above, resistin is associated with inflammation and insulin resistance, and also
direct effects of resistin on the myocardium have been demonstrated. Another possibility is a
yet undefined direct pathophysiologic role of resistin. Finally, a recent experimental study
showed that mechanical stretch enhances expression of resistin in cultured rat cardiomyocytes
via TNF-α31 Thus, the possibility that resistin concentrations reflect cardiac load cannot be
excluded.
What are the clinical implications of these results? First, considering the novelty of our data,
these results will need to be replicated in other populations. If these results are consistent in
other studies, then it is conceivable that serum resistin measurements may aid in improved
identification of elderly subjects, beyond usual risk factors, at high risk for HF. Similarly, as
the pathophysiology of new onset HF in general and the physiologic effects of resistin in
specific are better understood, it is possible that serum resistin concentrations may help guide
therapy. For example, neutralization of resistin activity by injection of antibodies against
resistin decreases blood glucose levels and improves insulin sensitivity in obese, insulin-
resistant mice.20 Most data on resistin currently however are derived from mice. Energy
metabolism in human differs from mice and therefore it is not known how much of the resistin
physiology in mice is applicable to humans. Thus, the role of resistin in modulating HF risk
remains speculative at this point.
Our study has several limitations. Diagnosis of HF was based on HF hospitalization. Because
some participants may have developed HF without hospitalization, HF rates are likely
underestimated. Echocardiography was not performed at baseline. Thus, the association of
resistin concentrations with structural characteristics of the heart could not be assessed. Resistin
has been shown to modulate release of natriuretic peptides in experimental studies.13,30
However, baseline concentrations of B-type natriuretic peptide (BNP) were not available; thus,
we could neither evaluate for possible correlation of resistin with BNP nor adjust for BNP in
multivariable models. Ventricular function during hospitalization for HF was not prospectively
assessed in Health ABC. The available data on ejection fraction were abstracted from medical
records (i.e., the studies were not centrally read), and do not refer to a single modality since
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ejection fraction values were derived from echocardiography or left ventriclurography reports
during hospitalization for HF. Therefore, the differential association of resistin with risk for
HF with preserved vs. reduced ejection fraction should be interpreted with caution. Because
our cohort included persons of age 70 or older, these findings might not apply in younger
populations. Although every effort was taken to control for potential confounders, we cannot
exclude the possibility of unmeasured confounding as an alternative explanation of the
observed findings. Finally, temporal trends in the use of new classes of drugs or growing use
of existing drugs to treat HF risk factors like hypertension or CHD may impact the risk of HF
development related to those risk factors. Thus risk estimates for any given risk factors may
change over time necessitating periodic reassessment in contemporary cohorts.
In conclusion, in this study we demonstrate that serum resistin concentrations independently
predict risk for incident HF among older persons. The practical implications of this finding in
terms of diagnostic and therapeutic uses need further study.
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Figure 1.
Baseline serum resistin concentrations and incident heart failure rates (per 1000 person years)
among participants without prevalent HF at baseline in the Health ABC Study. Error bars
represent 95% confidence intervals.
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Table 1
Baseline participant characteristics and correlation with resistin concentrations
Variable Value rho* P value
Age, years 73 (71, 76) 0.061 0.001
Male sex, % 48.1 0.040 0.030
Black race, % 41.2 0.039 0.035
Body mass index, kg/m2 26.8 (24.1, 30.1) 0.090 <0.001
Weight, kg 75.0 (65.3, 85.0) 0.104 <0.001
Waist circumference, cm 99.2 (91.5, 107.0) 0.096 <0.001
Thigh circumference, cm 50.8 (47.1, 55.0) 0.047 0.012
Waist/thigh circumference ratio 1.95 (1.80, 2.08) 0.054 0.003
Diabetes mellitus, % 14.7 0.075 <0.001
Hypertension, % 43.5 0.122 <0.001
Coronary heart disease, % 16.5 0.056 0.003
Left ventricular hypertrophy, % 11.9 0.018 0.34
Smoking, current %† 10.4 0.022 0.23
Alcohol consumption, % −0.054‡ 0.004
 Never 49.8
 Occasional 21.2
 1–7 drinks/week 21.6
 8 drinks/week 7.4
Physical activity, kcal/kg/week 65.2 (38.5, 107.5) −0.047 0.017
Systolic blood pressure, mg/dl 134 (122, 148) 0.055 0.003
Diastolic blood pressure, mg/dl 71 (64, 79) −0.006 0.73
Heart rate, bpm 64 (57, 72) 0.050 0.006
Fasting glucose, mg/dl 94 (87, 105) 0.066 <0.001
Albumin, gm/dl 4.0 (3.8, 4.2) −0.030 0.11
Creatinine, mg/dl 1.0 (0.9, 1.2) 0.248 <0.001
Total cholesterol, mg/dl 201 (177, 226) −0.067 <0.001
Low density lipoprotein, mg/dl 120 (99, 143) −0.049 0.009
High density lipoprotein, mg/dl 52 (42, 63) −0.098 <0.001
Triglycerides, mg/dl 117 (88, 162) 0.074 <0.001
Values for continuous variables represent median (interquartile range).
*
Spearman’s rank correlation rho for continuous variables; for binary variables (present=1, absent=0), the z score of the rank sum test is transformed into
the corresponding rho value for comparison purposes; rho=1 denotes perfect positive correlation, rho=−1 denotes perfect negative correlation, and rho=0
absent correlation.
‡
Nonparametric trend converted to corresponding rho value
†
Past and never smoker categories were collapsed for this analysis
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Table 2
Strength of association with incident heart failure risk
Variable Form* LR X2† P value C
Resistin, μg/mL Linear 43.8 <0.001 0.638
Interleukin-6, pg/mL 1/√x 69.4 <0.001 0.657
Tumor necrosis factor α, pg/mL Linear 44.1 <0.001 0.638
C-reactive protein, μg/mL 1/√x 28.5 <0.001 0.627
Hemoglobin A1c, % Linear 18.0 <0.001 0.614
Fasting insulin, μIU/mL Linear 2.7 0.103 0.595
Adiponectin, μg/mL Linear 1.0 0.320 0.593
Leptin, ng/mL Linear 3.0 0.082 0.595
DEXA – total fat mass, kg Linear 3.8 0.052 0.596
DEXA – percent body fat, % Linear 2.0 0.156 0.593
DEXA – trunk fat mass, kg Linear 7.4 0.007 0.600
CT – abdominal total area, cm2 Linear 6.1 0.013 0.599
CT – abdominal visceral fat area, cm2 Linear 12.5 <0.001 0.606
CT – abdominal subcutaneous fat area, cm2 Linear 0.4 0.507 0.592
*
Evaluated by first and second order fractional polynomial functions in univariable Cox models.
†
Adjusted for age, gender, and race.
CT: computed tomography; DEXA: dual X-ray absorptiometry; LR: likelihood ratio
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Table 3
Serum resistin concentrations and incident heart failure risk in adjusted models
Variable HR (95% CI) P value
Model 1 – Predictors of incident heart failure * 1.22 (1.12–1.33) <0.001
Model 2 – Model 1 plus clinical correlates of resistin † 1.22 (1.11–1.33) <0.001
Model 3 – Model 2 plus serum markers ‡ 1.16 (1.06–1.27) 0.002
Model 4 – Model 3 plus adiposity parameters § 1.15 (1.05–1.27) 0.003
Hazard ratios are calculated per standard deviation (10.0 ng/mL) of resistin concentrations.
*
Includes age, history of coronary heart disease and smoking, systolic blood pressure and heart rate, electrocardiographic left ventricular hypertrophy,
and serum levels of creatinine, fasting glucose, and albumin.12
†
Clinical parameters from Table 1 not included in model 1 with a significant (p<0.05) correlation with serum resistin concentrations.
‡
Inflammatory markers (C reactive protein, interleukin-6, tumor necrosis factor-α), insulin resistance markers (HbA1c, insulin), and adipocytokines (leptin,
adiponectin).
§
Computed tomography (abdominal total, visceral, and subcutaneous fat area) and dual X-ray absorptiometry (total and trunk fat, percent body fat) derived
adiposity parameters.
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